The biological rationale for targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) as a lipid-lowering strategy emerged from human genetics before it was explored in drug development. Loss-of-function variants in the PCSK9 gene were identified in cohorts with familial hypocholesterolaemia-like phenotypes characterised by markedly low LDL cholesterol concentrations and substantially reduced lifetime cardiovascular event rates a natural experiment demonstrating that sustained, profound LDL-C reduction from early life produces cardiovascular protection that exceeds what clinical trials of finite duration can replicate. The two approved PCSK9 inhibitors in the UK evolocumab (Repatha; Amgen) and alirocumab (Praluent; Sanofi/Regeneron) are fully human or humanised monoclonal antibodies that exploit this biological insight by blocking circulating PCSK9 and producing LDL-C reductions of 50% to 60% on top of background statin therapy.
This article explains the mechanism through which PCSK9 inhibition produces LDL-C reduction, what the FOURIER and ODYSSEY OUTCOMES trials established about cardiovascular benefit, and what the UK prescribing position looks like under current NICE criteria.
The PCSK9 Mechanism and Why Statins Leave a Gap
LDL cholesterol is cleared from the circulation primarily by LDL receptors (LDLR) expressed on the surface of hepatocytes. After binding an LDL particle and internalising it, the LDLR recycles to the cell surface for another round of LDL capture a recycling process that is the primary mechanism by which hepatocytes regulate circulating LDL-C. Statins lower LDL-C by inhibiting HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, which reduces intracellular cholesterol availability and upregulates LDLR expression on hepatocytes. The increased LDLR density clears more circulating LDL, reducing plasma LDL-C. This mechanism is effective but self-limiting: as statin dose increases, the compensatory upregulation of PCSK9 that accompanies reduced intracellular cholesterol increasingly degrades the very LDLR population that statins are designed to augment.
PCSK9 is a serine protease synthesised and secreted primarily by hepatocytes. Its physiological function is to bind the extracellular domain of LDL receptors and target them for lysosomal degradation rather than cell-surface recycling a feedback mechanism that limits the hepatocyte's capacity for LDL clearance. When PCSK9 binds LDLR on the hepatocyte surface or in the endosomal compartment, the receptor-ligand complex is directed to lysosomes where LDLR is degraded rather than recycled. The net effect is a reduction in LDLR density and an increase in circulating LDL-C.
PCSK9 inhibitors are monoclonal antibodies that bind circulating PCSK9 with high affinity, preventing it from binding LDLR. With PCSK9 neutralised, LDLR recycling proceeds without competitive interference, LDLR surface density on hepatocytes increases substantially, and LDL-C clearance increases correspondingly. Evolocumab binds PCSK9 at its catalytic domain and disrupts its interaction with LDLR. Alirocumab targets a slightly different epitope on PCSK9. Both achieve sustained PCSK9 suppression between fortnightly or monthly subcutaneous doses because of their prolonged half-lives (approximately 11 to 20 days) relative to the PCSK9 turnover rate.
The statin pharmacology is directly relevant here: statins increase PCSK9 expression as part of their downstream effects, which partially counteracts the LDLR upregulation that is their primary mechanism. This is the molecular basis for the ceiling effect of statin monotherapy higher statin doses produce diminishing returns on LDL-C reduction not purely because of tolerability limits but because rising PCSK9 levels degrade the LDLR population that statins are inducing. Adding a PCSK9 inhibitor to maximally tolerated statin therapy removes this ceiling by neutralising the PCSK9-mediated LDLR degradation that high-dose statin use is simultaneously accelerating.
Real fact: Loss-of-function variants in PCSK9 in humans are associated with lifelong LDL-C reductions of 15% to 28% and a 47% to 88% reduction in coronary heart disease risk compared with the general population, the human genetic evidence that established PCSK9 as a valid therapeutic target before any clinical trial was conducted.
What FOURIER Confirmed
The FOURIER trial (Sabatine et al., New England Journal of Medicine, 2017) was a multicentre, double-blind, placebo-controlled Phase 3 trial enrolling 27,564 patients with established atherosclerotic cardiovascular disease on optimised statin therapy, randomised 1:1 to evolocumab (either 140mg fortnightly or 420mg monthly subcutaneous injection) or matched placebo. The primary composite endpoint was cardiovascular death, myocardial infarction, stroke, hospitalisation for unstable angina, or coronary revascularisation; the key secondary endpoint was the harder composite of cardiovascular death, MI, or stroke.
At a median follow-up of 2.2 years, the primary endpoint occurred in 9.8% of evolocumab-treated patients versus 11.3% in the placebo group (HR 0.85; 95% CI: 0.79 to 0.92; p < 0.001). The key secondary endpoint occurred in 5.9% versus 7.4% (HR 0.80; 95% CI: 0.73 to 0.88; p < 0.001). LDL-C was reduced from a median baseline of 2.4 mmol/L to 0.78 mmol/L in the evolocumab arm, an absolute reduction of approximately 1.6 mmol/L and a percentage reduction of approximately 59%. The cardiovascular benefit was consistent across prespecified subgroups including patients on high-intensity versus moderate-intensity statins.
The relative risk reduction in the harder secondary endpoint of 20% translates to a number needed to treat of approximately 67 patients over 2.2 years to prevent one cardiovascular death, MI, or stroke. The NNT appears modest in absolute terms and becomes more favourable with longer treatment duration, an important consideration given the genetic evidence that sustained PCSK9 suppression produces cardiovascular benefit that compounds over decades rather than years. The FOURIER trial was sponsored by Amgen; multiple investigators declared relationships with Amgen and Sanofi/Regeneron, consistent with the trial's commercial sponsorship.
Cardiovascular mortality was not statistically significantly reduced in FOURIER at the 2.2-year follow-up a finding that attracted discussion at the time of publication and that the investigators attributed to the relatively short follow-up duration relative to what would be needed to demonstrate a mortality signal on top of a background of optimised statin therapy. The FOURIER Open Label Extension study, following a subset of participants for up to 8.4 years, reported in subsequent publications that mortality benefit became apparent with longer follow-up, providing some support for the hypothesis that duration of LDL-C lowering is a meaningful determinant of cardiovascular mortality reduction.
What ODYSSEY OUTCOMES Added
The ODYSSEY OUTCOMES trial (Schwartz et al., New England Journal of Medicine, 2018) evaluated alirocumab (75mg or 150mg fortnightly) in 18,924 patients with a recent acute coronary syndrome who were on optimised statin therapy. At a median follow-up of 2.8 years, the primary endpoint, a composite of coronary heart disease death, non-fatal MI, fatal or non-fatal ischaemic stroke, or unstable angina requiring hospitalisation occurred in 9.5% of alirocumab-treated patients versus 11.1% in the placebo group (HR 0.85; 95% CI: 0.78 to 0.93; p < 0.001). All-cause mortality was pre-specified as a secondary endpoint and showed a nominally significant reduction in the alirocumab arm (HR 0.85; 95% CI: 0.73 to 0.98; p = 0.026) the first statistically significant mortality signal in a PCSK9 inhibitor outcomes trial, though it was a secondary endpoint and requires interpretation in the context of the overall trial hierarchy. The trial was sponsored by Sanofi and Regeneron; multiple investigator conflicts were declared consistent with the trial's commercial context.
The UK Prescribing Position and NICE Criteria
In the United Kingdom, NICE technology appraisal TA394 (evolocumab, 2016) and TA393 (alirocumab, 2016) established the initial NHS access criteria for PCSK9 inhibitors. Both recommendations were more restrictive than the licensed indications, reflecting NICE's cost-effectiveness analysis at the then-prevailing list prices. Subsequent commercial renegotiations and updated guidance have expanded access modestly, but PCSK9 inhibitors remain subject to specific clinical criteria rather than being available to all patients with LDL-C above a threshold.
The current NICE criteria require, broadly, that patients have primary hypercholesterolaemia or mixed dyslipidaemia and at least one of the following: a diagnosis of established cardiovascular disease with inadequate LDL-C control despite maximally tolerated statin plus ezetimibe therapy; familial hypercholesterolaemia with a history of cardiovascular disease or at high risk of a cardiovascular event; or statin intolerance with inadequate LDL-C control on non-statin therapy. The specific LDL-C thresholds for treatment initiation vary between indications and between the two approved agents and should be confirmed against the current NICE guidance rather than recalled from the original appraisal, as several amendments have occurred since 2016.
Prescribing outside NICE criteria in NHS practice requires individual funding request (IFR) approval or access through a clinical trial. The Blueteq system is used in England to confirm NICE criteria eligibility at the point of prescribing; prescribers who do not complete Blueteq confirmation will not have prescriptions dispensed in NHS practice.
What Remains Unanswered
The mechanistic case for PCSK9 inhibition is among the most robust in cardiovascular pharmacology supported by human genetics, preclinical biology, biomarker evidence, and two large outcomes trials. What remains unanswered is not whether PCSK9 inhibition reduces cardiovascular events, but at what LDL-C target and in which patient populations the magnitude of incremental benefit justifies the cost above optimised statin plus ezetimibe. The NICE criteria represent a health economic answer to that question at a specific price point; the clinical answer, when longer follow-up data from the FOURIER extension and real-world registry studies mature, may support a broader patient definition.
The arrival of inclisiran a small interfering RNA (siRNA) therapeutic targeting PCSK9 mRNA that received MHRA authorisation in 2020 and NICE approval in 2021 adds a third mechanism for PCSK9 suppression with a distinct dosing schedule (twice yearly) and a different manufacturing and commercial cost structure that may change the access economics of this target over the coming decade. Whether siRNA-based PCSK9 suppression produces the same cardiovascular outcomes as monoclonal antibody-mediated PCSK9 inhibition is being addressed in the ongoing ORION-4 outcomes trial.
PCSK9 as a biological target was identified not in a pharmaceutical laboratory but in human families whose genetics showed what was possible. The drug development that followed is one of pharmacology's cleaner translations from genetic insight to approved medicine a story that is still completing its final chapters in outcomes data and access economics rather than basic science.
Related reading
How GLP-1 Receptor Agonists Reduce Cardiovascular Risk
